Fiche société
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Traitements, essais et publications liés.
Traitements14programmes
Essais7liés
Publications4liées
SourceDBlocale
Traitements
14| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| ACG102 InjectionThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of ACG102 administered via intravenous injection in patients with refractory active systemic lupus erythematosus (SLE) | Lupus | Phase 1 | À vérifier | À vérifier | |
| CART InfusionThis is a single-arm, open-label, investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of RD06-05 in subjects with autoantibody-mediated autoimmune hematological diseases. The enrolled population consists of patients with active autoimmune hematological diseases, including primary immune thrombocytopenic purpura (ITP), autoimmune hemolytic anemia (AIHA), and Evans syndrome. This study sets two dose groups: 6 × 10⁶ CAR⁺T cells/kg and 10 × 10⁶ CAR⁺T cells/kg, with the initial dose being 6 × 10⁶ CAR⁺T cells/kg. To reduce efficacy risks, the dose may be escalated to 10 × 10⁶ CAR⁺T cells/kg following evaluation and recommendation by the Safety Review Committee (SRC). The SRC's recommendation on dose escalation will be based on a comprehensive assessment of all available safety, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy data. | SEP | Phase 1 | Immunomodulation | China | À vérifier |
| Compound Ipratropium Bromide Solution(C1) for InhalationAcute exacerbation of chronic obstructive pulmonary disease (AECOPD) is an important event in the management of chronic obstructive pulmonary disease. Compound sodium chlolate and aminophylline tablets are one of the most widely used drugs for the treatment of bronchial asthma and chronic bronchitis. | SEP | Phase 4 | À vérifier | China | À vérifier |
| Compound Sodium Chlolate and Aminophylline Tablets(C2)Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is an important event in the management of chronic obstructive pulmonary disease. Compound sodium chlolate and aminophylline tablets are one of the most widely used drugs for the treatment of bronchial asthma and chronic bronchitis. | SEP | Phase 4 | À vérifier | China | À vérifier |
| EVM18001 InjectionA FIH, single arm, open-label, Investigator Initiated Trial (IIT) study to evaluate the safety and tolerability of EVM18001 in the treatment of active refractory autoimmune diseases (SLE, MG, and SSc), and determine the recommended dose for subsequent treatment. At the same time, the PK/PD characteristics of EVM18001 will be evaluated, preliminary efficacy will be observed, and related biomarkers and immunogenicity will be explored. | Myasthénie | Non applicable | China | À vérifier | |
| LCAR-AIO T cellsThis is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of LCAR-AIO in adult subjects with relapsed/refractory neurological autoimmune diseases. | Lupus, Myasthénie, SEP | Phase 1 | Immunomodulation | China | À vérifier |
| LVIVO-TaVec400 productThis is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed/refractory autoimmune diseases. | Lupus, Myasthénie, SEP | Phase 1 | China | À vérifier | |
| ACG102 InjectionThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of ACG102 administered via intravenous injection in patients with refractory active systemic lupus erythematosus (SLE) | Lupus | Phase 1 | À vérifier | À vérifier | |
| LCAR-AIO T cellsThis is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of LCAR-AIO in adult subjects with relapsed/refractory neurological autoimmune diseases. | SEP | Phase 1 | Immunomodulation + Thérapie cellulaire | China | À vérifier |
| LVIVO-TaVec400 productThis is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed/refractory autoimmune diseases. | Myasthénie | Phase 1 | China | À vérifier | |
| EVM18001 InjectionA FIH, single arm, open-label, Investigator Initiated Trial (IIT) study to evaluate the safety and tolerability of EVM18001 in the treatment of active refractory autoimmune diseases (SLE, MG, and SSc), and determine the recommended dose for subsequent treatment. At the same time, the PK/PD characteristics of EVM18001 will be evaluated, preliminary efficacy will be observed, and related biomarkers and immunogenicity will be explored. | Myasthénie | Non applicable | China | À vérifier | |
| Compound Ipratropium Bromide Solution(C1) for InhalationAcute exacerbation of chronic obstructive pulmonary disease (AECOPD) is an important event in the management of chronic obstructive pulmonary disease. Compound sodium chlolate and aminophylline tablets are one of the most widely used drugs for the treatment of bronchial asthma and chronic bronchitis. | SEP | Phase 4 | À vérifier | China | À vérifier |
| CART InfusionThis is a single-arm, open-label, investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of RD06-05 in subjects with autoantibody-mediated autoimmune hematological diseases. The enrolled population consists of patients with active autoimmune hematological diseases, including primary immune thrombocytopenic purpura (ITP), autoimmune hemolytic anemia (AIHA), and Evans syndrome. This study sets two dose groups: 6 × 10⁶ CAR⁺T cells/kg and 10 × 10⁶ CAR⁺T cells/kg, with the initial dose being 6 × 10⁶ CAR⁺T cells/kg. To reduce efficacy risks, the dose may be escalated to 10 × 10⁶ CAR⁺T cells/kg following evaluation and recommendation by the Safety Review Committee (SRC). The SRC's recommendation on dose escalation will be based on a comprehensive assessment of all available safety, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy data. | SEP | Phase 1 | Immunomodulation + Thérapie cellulaire | China | À vérifier |
| LCAR-AIO T cellsThis is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of LCAR-AIO in adult subjects with relapsed/refractory neurological autoimmune diseases. | Lupus | Phase 1 | Immunomodulation | China | À vérifier |
Essais cliniques
7| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| LCAR-AIO T cells | Lupus | Phase 1 | NCT06653556 | A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus | COMPLETED |
| CART Infusion | SEP | Phase 1 | NCT07441525 | UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases | RECRUITING |
| Compound Ipratropium Bromide Solution(C1) for Inhalation | SEP | Phase 4 | NCT04101500 | Effect of Compound Sodium Chlorate and Aminophylline Tablets on Chronic Obstructive Pulmonary Disease(COPD). | UNKNOWN |
| EVM18001 Injection | Myasthénie | Non applicable | NCT07470151 | Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases | RECRUITING |
| LVIVO-TaVec400 product | Myasthénie | Phase 1 | NCT07583030 | A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases | WITHDRAWN |
| LCAR-AIO T cells | SEP | Phase 1 | NCT06869278 | A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases | WITHDRAWN |
| ACG102 Injection | Lupus | Phase 1 | NCT07749430 | A Clinical Study of ACG102 Injection in Patients With Refractory Active Systemic Lupus Erythematosus | NOT_YET_RECRUITING |
Publications
4| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| EVM18001 Injection | Endoscopic Injection Sclerotherapy With Pre-deflation Ligation for Prolonged Sclerosant Retention in Esophageal Varices: A Case Report. | DEN open | ||
| LCAR-AIO T cells | Benzothiazole derivatives target oligoadenylate synthetase and enhance RSV vaccine efficacy as adjuvants. | Bioactive materials | ||
| LCAR-AIO T cells | Jianpi Bushen Qingchang Huashi formula alleviates DSS-induced colitis through butyrate-associated HDAC1 inhibition and Th17/Treg homeostasis. | Journal of ethnopharmacology | ||
| LCAR-AIO T cells | Lymphocytic Esophagitis Mimicking Eosinophilic Esophagitis and Esophageal Candidiasis: A Case Report. | DEN open |